About Wessex AHSN
Centre for Implementation Science
Frequently asked questions
The Access To Innovation Fund
The Access to Innovation Fund is a new grant fund focused on supporting people with early stage innovative ideas with the aim of enhancing patient ...
Recognising and Assessing Medical Problems in Psychiatric Settings (RAMPPS) training, 15th January 2018
Newsletters, annual reports...
100,000 patients are admitted for ventilation in the UK critical care units each year and 10-20% will go on to develop ventilated associated pneumonia (VAP). Between 3,000 and 6,000 people die from this type of pneumonia every year and prevention would save many lives. Treating VAP costs the NHS between £10,000 – £20,000 per patient and conservative estimates for prevention are savings to the NHS of over £100 million.
The PneuX system from Venner Medical is one example of the technology available. Full details from the manufacturer are here.
A video on VAP, and the use of PneuX is available here and full details from the award winning development team are here.
Collated evidence is available on the right, courtesy of North East and North Cumbria AHSN.
An economic impact model is also available on the right, courtesy of UCL Partners. Enter your regional population to cell B4 for an estimate of lives and money saved.
A retrospective review of patients managed with PneuX System
An in-vitro microbiological study comparing eight endotracheal tubes
Incidence of ventilator-associated pneumonia using the PneuX System
Performance of the PneuX System - A Bench Study Comparison With 4 Other Cuffs
PneuX for preventing ventilator-associated pneumonia in intensive care
Significant reduction in ventilator-associated pneumonia with the Venner-PneuX System
Economic Impact Model